|
Washington, D.C. — Leaders of Lombardi Cancer Center and Georgetown University Medical Center said today that Georgetown's recent clinical partnership with MedStar Health provides an opportunity to expand the range of services offered and the number of patients treated at Lombardi Cancer Center in the coming years.
"Georgetown's partnership with MedStar really enhances our clinical resources for treating cancer patients," said Kevin Cullen, MD, Interim Director of Lombardi. "That, coupled with the recruitment of a new director of the Lombardi Cancer Center, make this a particularly exciting time. Lombardi is known for its strong focus on breast cancer research and treatment, but recent changes here give us the opportunity to grow in other directions and build on the strengths we have developed over the years."
In June 2000, Georgetown University Medical Center and MedStar Health, Inc. finalized a clinical partnership agreement under which MedStar Health owns and operates Georgetown University's clinical enterprise, which includes the clinical operations of Lombardi Cancer Center. MedStar Health is a not-for-profit, community-based healthcare organization which includes eight major hospitals in the Baltimore/Washington area. Georgetown University continues to own and operate the education and research enterprises of the Medical Center, including the research and education components of Lombardi Cancer Center.
Sam W. Wiesel, MD, executive vice president and executive dean of Georgetown University Medical Center said, "Georgetown's recent partnership with MedStar Health has given us a number of tremendous opportunities, particularly in the area of translational research, which is especially important in the area of cancer." Wiesel added that the partnership has given Georgetown the resources to increase Lombardi's patient base. "The future of Lombardi has never been brighter."
The Lombardi Cancer Center has nearly 150 faculty members involved in translational cancer research, and supervises more than $55 million in sponsored research in areas including Tumor Biology, Cancer Genetics, Cancer Prevention, and Developmental Therapeutics. In addition, there are multiple training grants and programs within the Cancer Center including a degree-granting program in Tumor Biology.
John Richert, MD, chair of the search committee charged with finding a new director for Lombardi, said the committee is looking for an outstanding scientist with substantial research and clinical experience in oncology as well as significant administrative experience. A successful track record of peer-reviewed funding or the equivalent, as well as an active investigative program is also required. In addition to providing leadership to the Lombardi Cancer Center, the director also will serve as chair of Lombardi's Department of Oncology. Georgetown officials say they expect to have a new director identified by this summer. |
|
Georgetown University Medical Center is one of the nation's preeminent institutions of medical research and education. It includes a biomedical research enterprise, and the nationally ranked School of Medicine and School of Nursing and Health Studies. Lombardi Cancer Center, an important component of Georgetown University Medical Center, is one of only 38 Comprehensive Cancer Centers in the United States—and the only one in the Washington, D.C. area—designated by the National Cancer Institute.
|
